- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02162654
Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment (RIPAT)
The Role of Remote Ischemic Preconditioning in the Prevention of Ischemic Brain Damage During Intracranial Aneurysm Treatment (RIPAT) - A Prospective Randomized Exploratory Study
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Prospective, randomized, double-blind, explorative single center clinical trial in patients subjected to the treatment of an un-ruptured intracranial aneurysm, either by surgical clipping or endovascular coiling. Goal of the study is to determine whether remote ischemic preconditioning (RIPC) prior to aneurysm treatment alters various biomarkers associated with ischemic central neuronal tissue damage. The trial takes place at Innsbruck University Hospital of Innsbruck Medical University, Innsbruck, Austria.
Patients fulfilling inclusion criteria are randomly allocated either to pre-interventional ischemic preconditioning (Group A = intervention group) or sham preconditioning (Group B = control group). RIPC is performed by inflating a blood pressure cuff around one upper extremity three times for five minutes with five minutes interval with the patient under general anesthesia prior to the start of the procedure.
Patients, all staff involved in diagnosis and treatment and all study members are blinded to the patients' group affiliation. The anesthesiologist and two staff members who perform preconditioning are not blinded.
Primary outcome is a difference of ± 2SD in the concentration-time curve of a panel of biochemical parameters indicative of cerebral ischemia (S100B, NSE, GFAP, MMP9, MBP, microparticles) in the first five days after the intervention. Secondary outcome parameters are changes in the post-interventional MRI and neuropsychological and clinical outcome at six and 12 months.
CONSORT and TIDieR guidelines will be followed. The trail will be registered in a public database. The trail protocol will be published in an open-access journal.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Innsbruck, Österreich, 6020
- Rekrutierung
- Clinical Department of Neurosurgery, Innsbruck Medical University
-
Kontakt:
- Martin Ortler, M.D., MSc.
- Telefonnummer: 80975 0043-512-504
- E-Mail: martin.ortler@i-med.ac.at
-
Kontakt:
- Selma Tülü, Cand. med.
- E-Mail: selma.tuelue@student.i-med.ac.at
-
Hauptermittler:
- Martin Ortler, MD, MSc
-
Unterermittler:
- Claudius Thomé, M.D.
-
Unterermittler:
- Selma Tülü, Cand.med.
-
Unterermittler:
- Miriam Mulino, M.D.
-
Unterermittler:
- Daniel Pinggera, M.D.
-
Unterermittler:
- Claudia Unterhofer, M.D.
-
Unterermittler:
- Erich Schmutzhard, M.D.
-
Unterermittler:
- Bettina Pfausler, M.D.
-
Unterermittler:
- Ronny Beer, M.D.
-
Unterermittler:
- Raimund Helbok, M.D.
-
Unterermittler:
- Peter Lackner, M.D.
-
Unterermittler:
- Thomas Benke, M.D.
-
Unterermittler:
- Thomas Bodner, M.D.
-
Unterermittler:
- Margarethe Delazer, M.D.
-
Unterermittler:
- Raffaella Matteucci-Gothe, Ph.D.
-
Unterermittler:
- Uwe Siewert, Ph.D.
-
Unterermittler:
- Philipp Würtinger, M.D.
-
Unterermittler:
- Andrea Griesmacher, M.D.
-
Unterermittler:
- Markus Luger, M.D.
-
Unterermittler:
- Arnulf Benzer, M.D.
-
Unterermittler:
- Franz Wiedermann, M.D.
-
Unterermittler:
- Astrid Grams, M.D.
-
Unterermittler:
- Elke Gizewski, M.D.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Informed written consent of patient
- Age > 18 years
- Intracranial aneurysm, single or multiple, intervention as indicated by interdisciplinary vascular board (includes previously treated aneurysms)
- Normal baseline MRI
Exclusion Criteria:
- Clinical or radiological signs of subarachnoid hemorrhage
- Planned vessel sacrifice as the primary modality for aneurysm treatment
- Dissecting or mycotic aneurysm
- Previous history of stroke or TIA within the last six months
- Signs or symptoms of upper and lower extremity peripheral vascular illness
- Drugs and lifestyle factors that interfere with biomarker Determination
- Inability to complete neuropsychological testing for language reasons
- Patients unable to have an MRI scan for any reason
- Previous serious cerebral disease that would preclude completion of the protocol or preclude MRI analysis of small strokes
- Pregnancy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Remote ischemic preconditioning
Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
|
The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
|
|
Schein-Komparator: Sham preconditioning
Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
|
The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Area-under-Curve for biomarkers in the first 5 days after aneurysm treatment(S100B, NSE, GFAP, NSE, MMP9, Microparticles)
Zeitfenster: on admission, after preconditioning but prior to intervention, at completion of intervention, at hours 3, 6, 12, 24, 48, 72, 96, 120 after completion of intervention
|
Serum biomarkers reflect brain tissue ischemic damage with various specificity and sensitivity (see Whiteley 2008, Ahmad 2012) Advantages include (1) to be available early, (2) to be continuous variables (low study n), (3) they were able to demonstrate an effect of ischemic preconditioning in other clinical studies (see Koch 2010, Veighei 2012)
|
on admission, after preconditioning but prior to intervention, at completion of intervention, at hours 3, 6, 12, 24, 48, 72, 96, 120 after completion of intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number (n) of new lesions in postinterventional MRI (DWI and FLAIR)
Zeitfenster: preinterventional/on day 1 or 2
|
Outcome Parameter used in other clinical studies focussing on ischemia after neurointerventional procedures (e.g.
ENACT study)
|
preinterventional/on day 1 or 2
|
|
Clinical outcome ( National Institutes of Health Stroke Scale, NIHSS and modified Rankin Scale mRS)
Zeitfenster: at discharge, at 6 and 12 months
|
Established outcome parameters for cerebrovascular studies.
Dichotomized into favourable (NIHSS ≤1, mRS 0-1) and unfavourable
|
at discharge, at 6 and 12 months
|
|
Volume (mm3) of new lesions in postinterventional MRI (DWI and FLAIR)
Zeitfenster: preinterventional, postinterventional on day 1 or 2
|
As above for number of lesions
|
preinterventional, postinterventional on day 1 or 2
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Neuropsychological testing VLMTA (Verbaler Lern- und Merkfähigkeitstest), the WMS-R (Zahlenspanne vorwärts und rückwärts), trail making A and B tests, the Regensburger Wortflüssigkeitstest, the TAP Wechsel verbal, the TAP and the HADS-D)
Zeitfenster: preinterventional, at 6 and 12 months
|
Standard tests used in patients with cerebrovascular disorders in our departments.
Not applicable to non-german-speaking patients.
|
preinterventional, at 6 and 12 months
|
|
Brain volume changes (MRI, voxel -based morphometry)
Zeitfenster: Preinterventional/at the 12 months FU
|
Longterm brain volume changes that correlate with NP deficits (Horstmann 2010, Moskowitz 2011, Vuylsteke 2011) will be analyzed using voxel-based morphometry techniques
|
Preinterventional/at the 12 months FU
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Martin Ortler, M.D., MSc., Clinical Department of Neurosurgery, Innsbruck Medical University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 20131101-823
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .